Julie Andrews Sells 4,873 Shares of Orthofix Medical (NASDAQ:OFIX) Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CFO Julie Andrews sold 4,873 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $14.38, for a total value of $70,073.74. Following the transaction, the chief financial officer directly owned 58,039 shares of the company’s stock, valued at $834,600.82. The trade was a 7.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Orthofix Medical Price Performance

Shares of OFIX stock opened at $13.83 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.38 and a current ratio of 2.47. Orthofix Medical Inc. has a fifty-two week low of $10.24 and a fifty-two week high of $20.48. The firm has a market cap of $547.67 million, a P/E ratio of -4.56 and a beta of 0.79. The business’s 50 day moving average price is $15.25 and its 200-day moving average price is $14.35.

Hedge Funds Weigh In On Orthofix Medical

Institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC boosted its position in shares of Orthofix Medical by 67.7% in the 1st quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company’s stock worth $333,000 after purchasing an additional 8,241 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Orthofix Medical by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock valued at $335,000 after buying an additional 1,213 shares in the last quarter. Jane Street Group LLC purchased a new position in Orthofix Medical during the first quarter valued at $1,076,000. Strs Ohio bought a new stake in Orthofix Medical in the first quarter worth $150,000. Finally, Counterpoint Mutual Funds LLC bought a new stake in Orthofix Medical in the second quarter worth $301,000. Institutional investors own 89.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Barrington Research raised their target price on shares of Orthofix Medical from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus assumed coverage on shares of Orthofix Medical in a report on Tuesday, October 28th. They issued a “buy” rating and a $22.00 price objective for the company. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $21.50.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.